TY - JOUR
T1 - Clinical characteristics, EEG findings and implications of status epilepticus in patients with brain metastases
AU - Fox, Jonah
AU - Ajinkya, Shaun
AU - Greenblatt, Adam
AU - Houston, Peter
AU - Lekoubou, Alain
AU - Lindhorst, Scott
AU - Cachia, David
AU - Olar, Adriana
AU - Kutluay, Ekrem
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/12/15
Y1 - 2019/12/15
N2 - Purpose: To evaluate the clinical implications of status epilepticus in patients with metastases to the brain as well as associated demographic, clinical, EEG and radiographic features. Methods: Retrospective chart review of 19 patients with metastases to the brain who subsequently developed status epilepticus. Results: Of the patients who developed status epilepticus only 36.8% had a prior history of seizures since diagnosis of brain metastases. Status epilepticus most commonly occurred in the setting of a new structural injury to the brain such as new metastases, increase in size of metastases or hemorrhage. 57.9% of patients had either refractory or super-refractory status epilepticus. Focal non-convulsive status epilepticus was the most common subtype occurring in 42.1% of patients. 31.6% of patients died within 30 days of the onset of status epilepticus. Conclusion: Status epilepticus eventually resolved with treatment in all patients with brain metastases; however, it is associated with poor outcomes as nearly one-third was deceased within 30-days of onset. Nevertheless, no patients died during status epilepticus. Thus, status epilepticus may be indicative of an overall poor clinical status among patients with brain metastases.
AB - Purpose: To evaluate the clinical implications of status epilepticus in patients with metastases to the brain as well as associated demographic, clinical, EEG and radiographic features. Methods: Retrospective chart review of 19 patients with metastases to the brain who subsequently developed status epilepticus. Results: Of the patients who developed status epilepticus only 36.8% had a prior history of seizures since diagnosis of brain metastases. Status epilepticus most commonly occurred in the setting of a new structural injury to the brain such as new metastases, increase in size of metastases or hemorrhage. 57.9% of patients had either refractory or super-refractory status epilepticus. Focal non-convulsive status epilepticus was the most common subtype occurring in 42.1% of patients. 31.6% of patients died within 30 days of the onset of status epilepticus. Conclusion: Status epilepticus eventually resolved with treatment in all patients with brain metastases; however, it is associated with poor outcomes as nearly one-third was deceased within 30-days of onset. Nevertheless, no patients died during status epilepticus. Thus, status epilepticus may be indicative of an overall poor clinical status among patients with brain metastases.
UR - http://www.scopus.com/inward/record.url?scp=85073443632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073443632&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2019.116538
DO - 10.1016/j.jns.2019.116538
M3 - Article
C2 - 31644990
AN - SCOPUS:85073443632
SN - 0022-510X
VL - 407
JO - Journal of the neurological sciences
JF - Journal of the neurological sciences
M1 - 116538
ER -